


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 and R^2 independently represent halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₆ alkyl, polyhaloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, polyhaloC₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, aryl, heteroaryl, heterocyclyl, arylC₁₋₆ alkyl, heteroarylC₁₋₆ alkyl, heterocyclylC₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, -CO-aryl, -CO-heterocyclyl, -CO-heteroaryl, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group NR¹⁵R¹⁶, -NR¹⁵CO-aryl, -NR¹⁵CO-heterocyclyl, -NR¹⁵CO-heteroaryl, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ independently represent hydrogen or C₁₋₆ alkyl;

wherein said aryl, heteroaryl and heterocyclyl groups of R¹ and R² may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different and which are selected from halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, oxo, CF₃, OCF₃, CN, C₁₋₆ alkanoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylamido or C₁₋₆ alkylsulfonamido;

a and b independently represent 0, 1 or 2, such that a and b cannot both represent 0;


— is a single or double bond;

R³ represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

m and n independently represent 0, 1 or 2;

p represents an integer from 0 to 3, such that when p is an integer greater than 1, two R¹ groups may instead be linked to form a heterocyclyl group;

R⁴ represents -(CH₂)_q-NR¹¹R¹² or a group of formula (i):



wherein q is 2, 3 or 4;

R¹¹ and R¹² independently represent C₁₋₆ alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group optionally substituted by one or two R¹⁷ groups;

R¹³ represents hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-aryl or heterocyclyl;

R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, OH, diC₁₋₆ alkylamino or C₁₋₆ alkoxy;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;

or solvates thereof.

2. (Original) A compound as defined in claim 1 wherein R¹ represents halogen, hydroxy, cyano, nitro, -NR¹⁵R¹⁶, -NR¹⁵COR¹⁶, polyhaloC₁₋₆ alkyl, heterocyclyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkanoyl, arylsulfonamido, arylaminosulfonyl, -NR¹⁵SO₂R¹⁶, -SO₂NR¹⁵R¹⁶, -CO-heterocyclyl or two R¹ groups are linked to form a heterocyclyl group.

3. (Original) A compound as defined in claim 2 wherein p represents 1 and R¹ represents fluoro or cyano.

4. (Currently Cancelled)

5. (Currently Amended) A compound as defined in ~~any one of claims 1 to 4~~ claim 1 wherein m represents 1 and R² represents C₁₋₆ alkyl, arylC₁₋₆ alkyl, aryl or heteroaryl.

6. (Currently Cancelled).

7. (Currently Amended) A compound as defined in ~~any one of claims 1 to 6~~ claim 1 wherein n represents 1 and R³ represents halogen or polyhaloC₁₋₆ alkyl.

8.-11. (Currently Cancelled).

12. (Currently Amended) A compound as defined in ~~any one of claims 1 to 11~~ claim 1 wherein R⁴ represents -(CH₂)_q-NR¹¹R¹², q represents 3 and NR¹¹R¹² represents unsubstituted piperidine.

13. (Currently Cancelled).

14. (Currently Amended) A compound according to claim 1 which is selected from the group consisting of:

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,4-dihydro-1H-isoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-bromoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indole;
5-Fluoro-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;
5-Methoxy-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-fluoroindoline;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methylindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1,2,3,4-tetrahydroquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-nitroisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-aminoisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(1-succinimido)-isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(2-oxo-pyrrolidin-1-yl)-isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-2-trifluoromethyl-benzoyl]isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-cyano-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2,3,4,5-tetrahydro-1H-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,3-dimethylindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-methoxy-6-trifluoromethyl-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(dimethylaminosulfonyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfinyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfonyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-acetyl-indoline;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methyl-1,2,3,4-tetrahydroquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-methyl-1,2,3,4-tetrahydroquinoline;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-benzyl-1,2,3,4-tetrahydroisoquinoline;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(phenylsulfonamido)-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-(phenylaminosulfonyl)-1,2,3,4-tetrahydroisoquinoline;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-methoxyisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-trifluoromethylisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetylamino-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonamido-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6,7,8,9-tetrahydro-5*H*-[1,3]dioxolo[4,5-*h*][3]benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-8,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7-hydroxy-8-methylsulfonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-methoxyphenyl)-6,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-thienyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-bromo-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(\pm)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-*i*-propylsulfonyl)-6-chloro-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-fluoro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7,8-dichloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-8-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-2,3,4,5-tetrahydro-1*H*-3-benzazepine; N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-4-fluoroisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-cyanoisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(pyrrolidin-1-yl)carbonyl]isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(morpholin-4-yl)carbonyl]isoindoline;
N-[2-Chloro-4-(3-Piperidin-1-ylpropoxy)benzoyl]isoindoline;
N-[2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl]isoindoline;
N-[2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl]-5-fluoro-isoindoline;
N-[2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl]isoindoline; or
N-[2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl]-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

15. (Currently Amended) A compound according to claim 1 which is selected from the group consisting of:

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-fluoroisoindoline;

N-{4-[(1-Cyclobutyl-4-piperidinyloxy]benzoyl}isoindoline; or
N-{4-[(1-Cyclobutyl-4-piperidinyloxy]benzoyl}-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

16. (Original) A compound according to claim 1 which is N-[4-(3-piperidin-1-ylpropoxy)benzoyl]isoindoline or a pharmaceutically acceptable salt thereof.

17. (Currently Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in ~~any one of claims 1 to 16~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.


18.-20. (Currently Cancelled).

21. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in ~~any one of claims 1 to 16~~ claim 1 or a pharmaceutically acceptable salt thereof.


22. (Currently Cancelled).

23. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)




with a compound of formula (III)



or a protected derivative thereof, wherein R¹, R², R³, R⁴, a, b, m, n and p are as defined in claim 1 and L is OH or a suitable leaving group; or

(b) preparing a compound of formula (I) wherein R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ which comprises reacting a compound of formula (IV)



wherein R^1 , R^2 , R^3 , a , b , m , n , p and q are as defined in claim 1 and L^1 represents a suitable leaving group with a compound of formula $HNR^{11}R^{12}$; wherein R^{11} and R^{12} are as defined in claim 1; and optionally thereafter

(c) deprotecting a compound of formula (I) which is protected; and optionally thereafter

(d) interconversion to other compounds of formula (I).